Pipeline & science

Nitric oxide-donating research applied to eye diseases.

Glaucoma
Allergic conjunctivitis
Retina

Our portfolio, status as of Oct 21, 2026
Program	Preclinical	Partners
NCX 470 NO-donating bimatoprost ophthalmic solution 0.1%	NDA under review (U.S., China) · Phase 3 ongoing in Japan	Kowa — Japan, U.S. and all other territories outside China, Korea and Southeast Asia Ocumension Therapeutics — China, Korea and Southeast Asia
NCX 1728 NO-donating PDE5 inhibitor	Preclinical research	Glaukos — Research and global licensing option agreement
VYZULTA® Latanoprostene bunod ophthalmic solution 0.024%	Marketed in more than 15 countries	Bausch + Lomb — Worldwide
ZERVIATE® Cetirizine ophthalmic solution 0.24%	Marketed in the U.S. and China	Harrow — U.S. Ocumension Therapeutics — China and the majority of Southeast Asian markets

Our portfolio, status as of Oct 21, 2026

NCX 470
NO-donating bimatoprost ophthalmic solution 0.1%

NDA under review (U.S., China) · Phase 3 ongoing in Japan
- Kowa — Japan, U.S. and all other territories outside China, Korea and Southeast Asia
- Ocumension Therapeutics — China, Korea and Southeast Asia
NCX 1728
NO-donating PDE5 inhibitor

Preclinical research
- Glaukos — Research and global licensing option agreement
VYZULTA®
Latanoprostene bunod ophthalmic solution 0.024%

Marketed in more than 15 countries
- Bausch + Lomb — Worldwide
ZERVIATE®
Cetirizine ophthalmic solution 0.24%

Marketed in the U.S. and China
- Harrow — U.S.
- Ocumension Therapeutics — China and the majority of Southeast Asian markets

NCX 470

NO-donating bimatoprost ophthalmic solution 0.1%

NCX 470 is designed to release bimatoprost and NO into the eye to lower IOP by two different pathways. It has successfully completed two Phase 3 clinical trials, Mont Blanc and Denali; New Drug Applications have been submitted in the United States and in China, with a separate Phase 3 program ongoing in Japan.

Indication: Lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
Status: NDA under review (U.S., China) · Phase 3 ongoing in Japan
Next milestone: FDA target action date: Apr 30, 2027
Patents: Composition of matter patents until 2029 (potential extension of up to 5 years in the U.S. and EU); formulation patents to 2039 in the U.S., EU, Japan and China.
Partners: Kowa — Japan, U.S. and all other territories outside China, Korea and Southeast Asia; Ocumension Therapeutics — China, Korea and Southeast Asia

NCX 1728

NO-donating PDE5 inhibitor

NCX 1728 is an NO-donating Phosphodiesterase-5 (PDE5) inhibitor in preclinical research with potential for development in glaucoma, including neuroprotection, and retinal conditions.

Indication: Glaucoma (including neuroprotection) and retinal conditions
Status: Preclinical research
Next milestone: Potential option exercise by Glaukos
Partners: Glaukos — Research and global licensing option agreement

VYZULTA®

Latanoprostene bunod ophthalmic solution 0.024%

Exclusively licensed worldwide to Bausch + Lomb. At approval, VYZULTA was the first eye drop approved in the past 20 years with a novel approach to reduce IOP.

vyzulta.com

Indication: Glaucoma and ocular hypertension
Status: Marketed in more than 15 countries
Patents: Composition of matter patent to 2029 (U.S.)
Partners: Bausch + Lomb — Worldwide

ZERVIATE®

Cetirizine ophthalmic solution 0.24%

ZERVIATE is a novel, patented eye drop formulation of cetirizine approved in the U.S. for ocular itching associated with allergic conjunctivitis.

zerviate.com

Indication: Treatment of ocular itching associated with allergic conjunctivitis
Status: Marketed in the U.S. and China
Patents: Granted patents in the U.S. to 2030 and 2032, and in Europe, Japan and Canada to 2030
Partners: Harrow — U.S.; Ocumension Therapeutics — China and the majority of Southeast Asian markets

How nitric oxide works

01
NO

Nitric oxide is a small, naturally occurring signaling molecule.
02
sGC → cGMP

It stimulates soluble guanylate cyclase (sGC), which produces the second messenger cGMP.
03
Trabecular meshwork

Rising cGMP relaxes the trabecular meshwork.
04
Outflow ↑, IOP ↓

Aqueous humor outflow increases, which is thought to lower IOP.

NO is a well-known, small, naturally occurring signaling molecule known to stimulate an intracellular enzyme, soluble guanylate cyclase (sGC), which converts guanosine triphosphate to the second messenger, cyclic guanosine monophosphate (cGMP). NO/sGC signaling pathway plays a key role in the regulation of IOP homeostasis and ocular blood flow. The NO stimulated increase in cGMP in the trabecular meshwork leads to the reduction of intracellular calcium, relaxation of the trabecular meshwork and, consequently, an increase in the outflow of the aqueous humor from the anterior segment of the eye through the primary or conventional outflow pathway. All of the foregoing events are thought to lead to lowering of IOP and enhance ocular perfusion.

Watch the mechanism video (opens vimeo.com in a new tab)

Disease areas

Glaucoma

~80 million About 80 million people are estimated to be affected by the most common form of glaucoma

50% There are typically no early symptoms, which is why 50% of people with glaucoma don’t know they have the disease

Allergic conjunctivitis

75 million+ It is estimated that more than 75 million people suffer from allergic conjunctivitis in the United States

Retina

200 million About 200 million people are estimated to suffer from AMD

100 million About 100 million people are estimated to suffer from diabetic retinopathy

Glossary

IOP: Intraocular pressure: the fluid pressure inside the eye.
NDA: New Drug Application: the request for marketing approval filed with a regulator such as the U.S. FDA.
PDUFA date: The target date by which the U.S. FDA aims to complete its review of an application. It is not a guarantee of approval.
NO: Nitric oxide, a small signaling molecule naturally produced by the body.

Publications are available on nicox.com (opens nicox.com in a new tab)